- Home
- CRVO
CRVO
CervoMed Inc.
as 11-14-2025 3:27pm EST
CervoMed Inc is a clinical stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.
| Founded: | 2001 | Country: | United States |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | 65.2M | IPO Year: | N/A |
| Target Price: | $21.50 | AVG Volume (30 days): | 64.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.87 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.80 - $16.94 | Next Earning Date: | 11-10-2025 |
| Revenue: | $6,159,786 | Revenue Growth: | -38.81% |
| Revenue Growth (this year): | -33.05% | Revenue Growth (next year): | -87.48% |
Stock Insider Trading Activity of CervoMed Inc. (CRVO)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Gregoire Sylvie | CRVO | Director, 10% Owner | Nov 12 '25 | Buy | $7.35 | 5,553 | $40,814.55 | 1,467,131 | |
| ALAM JOHN J | CRVO | CEO & President | Nov 12 '25 | Buy | $7.35 | 5,553 | $40,814.55 | 1,467,131 | |
| ELDER WILLIAM ROBERT | CRVO | CFO, GC & Secretary | Nov 12 '25 | Buy | $7.44 | 3,500 | $26,040.00 | 9,000 |
Latest CervoMed Inc. News
CRVO Breaking Stock News: Dive into CRVO Ticker-Specific Updates for Smart Investing
GlobeNewswire
5 days ago
CervoMed Reports Third Quarter 2025 Financial Results and Provides Corporate Updates
Zacks
7 days ago
CervoMed Inc. (CRVO) Reports Q3 Loss, Misses Revenue Estimates
Zacks
8 days ago
Atara Biotherapeutics (ATRA) Surges 10.0%: Is This an Indication of Further Gains?
Zacks
8 days ago
Lexicon Pharmaceuticals (LXRX) Reports Q3 Loss, Beats Revenue Estimates
MT Newswires
9 days ago
CervoMed Shares Rise After HC Wainwright Upgrade
MT Newswires
9 days ago
HC Wainwright Upgrades CervoMed to Buy From Neutral, Adjusts Price Target to $25 From $11
GlobeNewswire
11 days ago
CervoMed Announces Alignment with FDA on Registration Path for Neflamapimod in Dementia with Lewy Bodies
Simply Wall St.
15 days ago
Here's Why We're Watching CervoMed's (NASDAQ:CRVO) Cash Burn Situation
Compare CRVO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CRVO CervoMed Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.